| 摘要: |
| 含 Src 同源 2 结构域蛋白酪氨酸磷酸酶2(Src homology 2 region-containing protein tyrosine phosphatase 2, SHP2)是由PTPN11编码的胞内非受体蛋白酪氨酸磷酸酶,已被证实参与多种癌症的发生发展,主要通过RAS/MAPK、PI3K/AKT、JAK/STAT、PD-L1/PD-1等信号通路调控肿瘤细胞生长、增殖、侵袭、凋亡和免疫逃逸。自2016年诺华团队发现了SHP2的变构位点开始,对其抑制剂的研究已从催化位点抑制剂转向新型的变构位点抑制剂,克服了催化位点抑制剂高极性和特异性差的缺点,目前已有许多小分子化合物被报道,且具有成药潜力的SHP2变构抑制剂相继被开发进入临床试验阶段。本文将重点介绍近五年文献报道的SHP2靶点的结构与功能、在肿瘤靶向治疗中的价值及其变构抑制剂的研究进展。 |
| 关键词: 含Src同源2结构域蛋白酪氨酸磷酸酶2 肿瘤靶向治疗 耐药 免疫抑制 变构抑制剂 |
| DOI:10.13506/j.cnki.jpr.2023.01.010 |
| 基金项目: |
|
出版日期:2023-01-25
|
|
| Research advances of protein tyrosine phosphatase SHP2 and its allosteric inhibitors in tumor-targeted therapy |
| LI Yuan1,2,LI Xue2,CHEN Zhen1 |
| (1.School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China; 2.Nanjing Sanhome Pharmaceutical Co., Ltd., Nanjing 210038, China) |
| Abstract: |
| Src homology 2 region-containing protein tyrosine phosphatase 2 (SHP2) is an intracellular non-receptor protein tyrosine phosphatase encoded by PTPN11. It has been confirmed to be involved in the occurrence and development of a variety of cancers, mainly regulating tumor cell growth, proliferation, invasion, apoptosis and immune escape through RAS/MAPK, PI3K/AKT, JAK/STAT, PD-L1/PD-1 and other signaling pathways. Since Novartis discovered the allosteric site of SHP2 in 2016, the research on its inhibitors has shifted from catalytic site inhibitors to novel allosteric site inhibitors, overcoming the disadvantages of high polarity and poor specificity of catalytic site inhibitors. Currently, many small molecule compounds have been reported. Moreover, SHP2 allosteric inhibitors with potential as patent drugs have been developed and entered into clinical trials. In this review, we will focus on the structure and function of SHP2 targets, their value in tumor targeted therapy and the progress of allosteric inhibitors reported in recent five years. |
| Key words: SHP2 tumor-targeted therapy drug resistance immunosuppressive allosteric inhibitors |